English

The exercise period for Prostatype Genomics AB’s warrants of series TO 2 commences today

Report this content

Prostatype Genomics AB ("Prostatype Genomics" or “the Company") announces that the exercise period for warrants of series TO 2 ("TO 2") begins today, March 9, 2023. The exercise period runs through March 30, 2023. Holders of TO 2 have the right to subscribe for one (1) new share in Prostatype Genomics at a price of SEK 2.90 per share for each warrant. Through full exercise of TO 2, the Company can receive a maximum of approximately SEK 22.5 million before issue costs. An information sheet is available on the respective websites of Prostatype Genomics (www.prostatypegenomics.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). A registration form is also available via Nordic Issuing AB's website.

In July 2022, Prostatype Genomics carried out an issue of units (shares and free-of-charge warrants of series TO 2). There are a total of 7,755,895 outstanding warrants of series TO 2, which during the exercise period 9-30 March 2023 give the holder the opportunity to subscribe for new shares at a rate of 2.90 per share. Through full use of TO 2, Prostatype Genomics can receive a maximum of approximately SEK 22.5 million before issue costs.

An information sheet is available on the respective websites of Prostatype Genomics (www.prostatypegenomics.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). To exercise warrants of series TO 2, the holder should best contact the bank where the holding is located. A registration form is also available via Nordic Issuing AB's website.

TO 2 in brief

  • Exercise price: each TO 2 gives the holder the right to subscribe for one (1) new share in Prostatype Genomics at a price of SEK 2.90 per share.
  • Issue amount: there are 7,755,895 outstanding TO 2. At full exercise of all TO 2’s Prostatype Genomics will receive approx. SEK 22.5 million before transaction related costs.
  • Outstanding shares in Prostatype prior to warrant exercise: 22,859,497 shares.
  • Ticker and ISIN: TO 2 are traded on Nasdaq First North Growth Market under the ticker ”PROGEN TO2” and ISIN-code SE0018220014.

Shares and share capital

Upon full exercise of TO 2, the number of shares in Prostatype Genomics will increase by 7,755,895 shares to 30,615,392 shares and the share capital will increase by SEK 465,353.70 to SEK 1,836,923.52. This entails a dilution of approximately 25 percent based on the number of outstanding shares in Prostatype Genomics after full utilization of TO 2.

Important dates TO 2

9 March 2023 – exercise period commences.

28 March 2023 – last day of trading in TO 2.

30 March 2023 – exercise period ends.

3 April 2023 – planned publication of outcome of warrant exercise.

21 April 2023 – planned date for change from interim shares to shares.

Advisors and issuing agent

Sedermera Corporate Finance AB is the financial advisor and Nordic Issuing AB is the issuing for Prostatype Genomics in connection with the warrant exercise. Markets & Corporate Law Nordic AB is the legal advisor.

For further information about TO 2, please contact

Sedermera Corporate Finance AB

Phone: +46 (0) 40 615 14 10

E-mail: cf@sedermera.se

Webpage: www.sedermera.se

Nordic Issuing AB

Phone: +46 (0) 40 632 00 20

E-mail: info@nordic-issuing.se

Webpage: www.nordic-issuing.se

Press Contact

Nicklas Rosendal
nicklas.rosendal@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Subscribe